Zarnestra
(Tipifarnib)Phase 2Small molecule
Tipifarnib is used to treat certain types of blood cancers, particularly acute myeloid leukemia (AML) in older adults who cannot tolerate standard chemotherapy. It works by blocking proteins that help cancer cells grow and divide.[1] Zarnestra is currently being investigated across 3 indications[3], with its most advanced program in Phase 2.[1]
Zarnestra is one of 93 small molecule programs targeting Malignant Solid Neoplasm. It is currently in Phase 2.
3
Indications
73
Total Trials
3
Active Trials
92
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
88 competitors in Neuroblastoma
#DrugCompanyPhaseTrials
1Cytoxan
BBaxter Healthcare Corporation
Phase 3
Vepesid
AAvyxa
Phase 3
Paraplatin
AAvyxa
Phase 3
Leukine
SanofiPhase 3
Camptosar
PfizerPhase 3
Tepadina
Jazz PharmaceuticalsPhase 3
Alkeran
AApotex Inc.
Phase 3
Accutane
CConrado Roberto Hoffmann Filho
Phase 3
Oncovin
Eli LillyPhase 3
Platinol
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Acute Myeloid Leukemia9 trials
Show 6 more trials
Breast Cancer8 trials
Glioblastoma Multiforme5 trials
Myelodysplastic Syndromes4 trials
Non-Small Cell Lung Cancer4 trials
Tipifarnib Plus Radiation Therapy After Combination Chemotherapy in Treating Patients With Stage III Non-Small Cell Lung Cancer
Completed·—·Phase 1·NCT00025480·12 enrolled
31 more indications
Patients With Advanced Solid Tumors3 trials
Pancreatic Cancer3 trials
Tipifarnib and Radiation Therapy in Treating Patients With Unresectable Locally Advanced Pancreatic Cancer
Completed·—·Phase 1·NCT00077519·18 enrolled
Advanced Cancer2 trials
Leukemia2 trials
Head and Neck Cancer2 trials
Chronic Myelogenous Leukemia2 trials
Lymphoma2 trials
Chronic Myelomonocytic Leukemia2 trials
Bladder Cancer2 trials
Melanoma2 trials
Malignant Glioma1 trial
Tipifarnib in Treating Patients With Recurrent or Progressive Malignant Glioma
Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 1/2·NCT00005859·136 enrolled
Advanced Solid Malignancies1 trial
Urothelial Carcinoma1 trial
Neurofibromatosis Type 11 trial
Neutropenia1 trial
Metastatic Cancer1 trial
Multiple Myeloma1 trial
Metastatic Prostate Cancer1 trial
HNSCC1 trial
Neuroblastoma1 trial
Advanced Malignant Solid Neoplasm1 trial
Malignant Solid Neoplasm1 trial
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Tipifarnib. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Mechanism of Action
- Protein Farnesyltransferase Inhibitor[2]
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- KKura Oncology, Inc.